Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs

Michael F. Powell, Donna J. Eastman, Amy Lim, Catherine Lucas, Michael Peterson, Joann Vennari, Robert P. Weissburg, Terri Wrin, Charlotte R. Kensil, Mark J. Newman, Jack Nunberg, Jeffrey L. Cleland, Tim J. Gregory, Phillip W. Berman

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


The immunogenicity of recombinant gp120 from the MN strain of HIV-1, a candidate HIV-1 vaccine, was evaluated in guinea pigs using adjuvant formulations with different physical and chemical properties. The adjuvants tested included Freund's adjuvant (FA), alum, and the novel adjuvant QS-21. These studies demonstrated that QS-21 provides a number of advantages compared to the two other adjuvants tested. QS-21 formulations accelerated the production of antibodies to MN rgp120 and elicited complete seroconversion after a single immunization. QS-21 shifted the antigen dose-response curve for antibody production by as much as three orders of magnitude, enabling a more economical use of antigen. Antibody titers to MN rgp120 and to the principal neutralizing determinant in the V3 domain were higher in animals receiving QS-21 formulations than in animals immunized with the other adjuvants, and correlated well with higher virus neutralization titers in an in vitro assay. These results support the testing of QS-21 in future clinical trials of candidate HIV-1 vaccines.

Original languageEnglish
Pages (from-to)203-209
Number of pages7
JournalAIDS Research and Human Retroviruses
Issue number2
StatePublished - Feb 1995


Dive into the research topics of 'Effect of Adjuvants on Immunogenicity of MN Recombinant Glycoprotein 120 in Guinea Pigs'. Together they form a unique fingerprint.

Cite this